SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010425
Filing Date
2019-11-07
Accepted
2019-11-07 17:01:33
Documents
86
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20190930x10q.htm 10-Q 3452803
2 EX-31.1 acrs-20190930ex311014d9d.htm EX-31.1 17141
3 EX-31.2 acrs-20190930ex31275097a.htm EX-31.2 17127
4 EX-32.1 acrs-20190930ex321c7591e.htm EX-32.1 10664
  Complete submission text file 0001558370-19-010425.txt   12075365

Data Files

Seq Description Document Type Size
5 EX-101.INS acrs-20190930.xml EX-101.INS 2946428
6 EX-101.SCH acrs-20190930.xsd EX-101.SCH 61255
7 EX-101.CAL acrs-20190930_cal.xml EX-101.CAL 79608
8 EX-101.DEF acrs-20190930_def.xml EX-101.DEF 211023
9 EX-101.LAB acrs-20190930_lab.xml EX-101.LAB 635142
10 EX-101.PRE acrs-20190930_pre.xml EX-101.PRE 436950
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 191201186
SIC: 2834 Pharmaceutical Preparations